Four Big Law Firms Guide GSK’s $10.6 Billion Nuvalent Buy

Davis Polk & Wardwell, Slaughter and May, Ropes & Gray and Sidley Austin steered GSK Plc’s plans to purchase Nuvalent Inc. for $10.6 billion.

The transaction comes as the British pharmaceutical company works to rebuild its oncology franchise. Nuvalent develops treatments for lung cancer.

Davis Polk and British firm Slaughter and May guided GSK.

Davis Polk’s corporate team includes William J. Chudd who is co-head of the firm’s private equity practice, and Daniel Brass, a partner who guides US, UK and other global M&A transactions. The duo has guided GSK on prior transactions, including the company’s acquisition of IDRx Inc. ...